The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients-Reference-Cited by-同舟云学术

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Published:2016-11-02 Issue:363 Volume:8 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Kennedy Matthew E.¹,Stamford Andrew W.²,Chen Xia¹,Cox Kathleen³,Cumming Jared N.²,Dockendorf Marissa F.³,Egan Michael⁴,Ereshefsky Larry⁵,Hodgson Robert A.¹,Hyde Lynn A.¹,Jhee Stanford⁵,Kleijn Huub J.³,Kuvelkar Reshma¹,Li Wei²,Mattson Britta A.⁶,Mei Hong³,Palcza John⁷,Scott Jack D.²,Tanen Michael⁸,Troyer Matthew D.⁹,Tseng Jack L.⁹,Stone Julie A.³,Parker Eric M.¹,Forman Mark S.⁹

Affiliation:

1. Department of Neuroscience, Merck Research Laboratories, Kenilworth, NJ 07033, USA.

2. Department of Global Chemistry, Merck Research Laboratories, Kenilworth, NJ 07033, USA.

3. Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, NJ 07033, USA.

4. Department of Clinical Research, Merck Research Laboratories, Kenilworth, NJ 07033, USA.

5. PAREXEL, Glendale, CA 91206, USA.

6. Department of Safety Assessment, Merck Research Laboratories, West Point, PA 19446, USA.

7. Department of Biostatistics, Merck Research Laboratories, Kenilworth, NJ 07033, USA.

8. Translational Biomarkers Department, Merck Research Laboratories, Kenilworth, NJ 07033, USA.

9. Department of Translational Medicine, Merck Research Laboratories, Kenilworth, NJ 07033, USA.

Abstract

The BACE1 inhibitor verubecestat safely reduces β-amyloid deposition in rats, monkeys, healthy human subjects, and patients with Alzheimer’s disease.

Funder

Merck & Co. Inc.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference42 articles.

1. Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years

2. The amyloid hypothesis of Alzheimer's disease at 25 years

3. Targeting the β secretase BACE1 for Alzheimer's disease therapy

4. Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior

5. Three dimensions of the amyloid hypothesis: time, space and 'wingmen'

Cited by 349 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging paradigms in Alzheimer's therapy;European Journal of Pharmacology;2024-10

2. Mesenchymal stem cell therapy for Alzheimer’s disease: A novel therapeutic approach for neurodegenerative diseases;Neuroscience;2024-09

3. It’s good to know what to BACE the specificity of your inhibitors on;Journal of Clinical Investigation;2024-08-15

4. Navigating the Maze of Alzheimer’s disease by exploring BACE1: Discovery, current scenario, and future prospects;Ageing Research Reviews;2024-07

5. The Alzheimer’s disease–linked protease BACE2 cleaves VEGFR3 and modulates its signaling;Journal of Clinical Investigation;2024-06-18